Anteotech Ltd · ASX:ADO
Anteotech — Investor Presentation (October 2026)
16 slides from Anteotech's investor presentation, Oct 22, 2026
Slide 1: AnteoBind market opportunities & partnership landscape
rsonal use only AnteoBind market opportunities & partnership landscape Life Sciences Business | Investor Presentation 22 October 2026 AnteoBind
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX: ADO) (AnteoTech). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordin
Slide 3: Who We Are
Who We Are One COMPANY INTRODUCTION proprietary rsonal use only chemical platform Two global markets Life Battery Chemical and Advanced Sciences Technologies Material solutions Multiple For life sciences and opportunities next-generation batteries Publicly listed company Established commercial suppl
Slide 4: Capital Structure and Corporate Overview
Capital Structure and Corporate Overview Capital Structure (as at 19 October 2026) Directors COMPANY OVERVIEW Glenda McLoughlin Cash in Bank $11.2 million total as at 30 June 2026 Non-Executive Chair Market Capitalisation (including Term Deposits) Investment Banker with rsonal use only $49 m Morgan
Slide 5: AnteoTech's Life Sciences Products
AnteoTech’s Life Sciences Products Early revenue business, operating in target markets which have ~US$90 billion in sales annually1 COMPANY INTRODUCTION Established Advanced chemical and materials solutions business and growing Two businesses: Life Sciences and Advanced Battery Technologies business
Slide 6: Global Commercialisation Strategy
Global Commercialisation Strategy Source: ASX release, 10 June 2025, Strategic Review Outcomes TIQ: Trade and Investment Queensland. JDA: Joint development agreement. Regional commercial strategy and market priorities. Existing markets New opportunities Europe COMPANY INTRODUCTION USA South Korea &
Slide 7: Life Sciences
rsonal use only LS INVESTOR PRESENTATION | 22 OCTOBER 2026 | ©AnteoTech Limited 7
Slide 8: AnteoTech's commercial position today in the Life Sciences market
AnteoTech’s commercial position today in the Life Sciences market TODAY Established Commercial Supply/Revenues Five-year take-or-pay US$ 1.8 million supply agreement with the Serum Institute of India rsonal use only signed in mid 2024. Growing International Distribution Network Established distribut
Slide 9: Lateral Flow: Broad Customer Base Across Global Diagnostics Markets
Lateral Flow: Broad Customer Base Across Global Diagnostics Markets AnteoBind supports antibody conjugation to particles used in rapid diagnostic tests. rsonal use only GLOBAL MARKET SIZE (2024) DISCUSSIONS UNDERWAY (SQL) ANTEOBIND TM APPLICATION US$15.5B 17 Across manufacturers, developers and Late
Slide 10: CLIA: Engaging with Global Diagnostic Manufacturers
CLIA: Engaging with Global Diagnostic Manufacturers AnteoBind supports antibody conjugation to magnetic beads used in automated chemiluminescence immunoassays (CLIA). rsonal use only GLOBAL MARKET SIZE (2024) DISCUSSIONS UNDERWAY (SQL) ANTEOBIND TM APPLICATION US$13B 9 Including four major global IV
Slide 11: ELISA: Expanding Opportunities in Diagnostic Microplates
ELISA: Expanding Opportunities in Diagnostic Microplates AnteoBind surface chemistry supports antibody and antigen immobilisation on microplates used in ELISA diagnostic assays. rsonal use only GLOBAL MARKET SIZE (2024) DISCUSSIONS UNDERWAY (SQL) ANTEOBIND TM APPLICATIONS US$21B 2 Both organisations
Slide 12: Biosensors: Expanding AnteoBind into Emerging Diagnostic Applications
Biosensors: Expanding AnteoBind into Emerging Diagnostic Applications AnteoBind supports the immobilisation of biomolecules on sensor surfaces for potential biosensor applications. rsonal use only GLOBAL MARKET SIZE (2025) DISCUSSIONS UNDERWAY (SQL) ANTEOBIND TM APPLICATION US$34.5B 3 Sensor Surface
Slide 13: Multiple Applications, Expanding Commercial Opportunities
Multiple Applications, Expanding Commercial Opportunities One proprietary surface chemistry platform and customer engagement globally across established and emerging diagnostic markets and applications. rsonal use only LATERAL FLOW CLIA ELISA BIOSENSORS 17 9 2 3 Latex and gold particle Magnetic bead
Slide 14: Expanding Market Reach Through Potential Life Sciences Partnerships
Expanding Market Reach Through Potential Life Sciences Partnerships Supply partnerships can bring AnteoBind to large and established IVD customer bases rsonal use only PARTICLE MANUFACTURERS 3 potential partners are being engaged with Global OEM reagent Life sciences manufacturer multinational Micro
Slide 15: Expanding AnteoBind across the Diagnostics Value Chain
Expanding AnteoBind across the Diagnostics Value Chain Moving beyond reagent supply to integrate and embed AnteoBind into assays and new platforms Surface chemistry Particles & plates New diagnostic platforms RESULT AnteoBind in more products rsonal use only TODAY MOVE 1 MOVE 2 Reagent sold to diagn
Slide 16: Thank You
rsonal use only THANK YOU Contact: Merrill Gray investors@anteotech.com +61 (07) 3219 0085 www.anteotech.com